Blogs

Cannabinoid Based Pharmaceutical Products

By September 9, 2020 No Comments
cannabinoid products

The two most abundant cannabinoids are cannabidiol and tetrahydrocannabinol – widely known as CBD and THC respectively. The strain of the cannabis plant determines the breakdown of cannabinoid composition – whether higher in CBD or THC. Hemp, for example, is naturally higher in CBD and contains a very low amount of THC.

So how do we get from the cannabis plant to a cannabinoid-based product?

Harvesting

From the start, it is extremely important to have the right technology and processes in place to make use of the entire hemp flower in preparation for extraction and isolation. Trichome Ag provides a proprietary 9-stage hemp biomass processing platform. This allows for optimization across the board – making use of the whole hemp plant while providing 100% purity. Trichome Ag’s 8,000 sq. ft facility can process 30,000 acres plus annually.

Extraction and Isolation

In a previous article, we discussed the most popular extraction methods and the pros and cons of each. Kalmex & Nectar are both leading the way through innovation and industry firsts. Kalmex has a 25-year exclusive global license to use proprietary membrane-based technology to produce full spectrum cannabinoid extracts. Kalmex uses a water & certified organic non-GMO ethanol solvent to create organic Full-Spectrum Extracts at a fraction of the variable cost of other technologies.

Nectar, on the other hand, focusses on isolation technologies – selectively targeting and isolating the desired cannabinoids at a purity of >99% from Hemp or Marijuana extract. Nectar has the capability to produce up to 1 tonne of cannabinoid isolates per day in a processing facility that utilizes 20 tonnes of biomass consisting of 5% concentration of the desired cannabinoid. They can successfully isolate CBDA, CBD, THCA, and THC cannabinoids.

Endocannabinoid receptors

These receptors are found throughout your body. Endocannabinoids bind to them in order to signal that the ECS needs to take action.

There are two main endocannabinoid receptors:

  • CB1 receptors, which are mostly found in the central nervous system
  • CB2 receptors, which are mostly found in your peripheral nervous system, especially immune cells

Endocannabinoids can bind to either receptor. The effects that result depend on where the receptor is located and which endocannabinoid it binds to.

THC, widely considered the stronger of the two main cannabinoids, has such a powerful impact on the body – partly because it can bind to both CB1 and CB2 receptors.

CBD on the other hand does not bind to CB1 or CB2 in the same way as THC and while having many use cases, does not carry the same side effects. 

Pharmaceutical Products

Until recently, cannabinoids THC and CBD were widely restricted under legislation which stated they had no medical value and carried a substantial risk of misuse. Policy is rapidly changing, as research is proving otherwise and in many countries, cannabis can now be prescribed for medicinal uses such as:

  • Pain
  • Helping To Decrease Opioid Use
  • Anxiety
  • Epilepsy
  • Glaucoma
  • HIV/AIDS Symptoms
  • Inflammatory Bowel Disease
  • Irritable Bowel Syndrome
  • Movement Disorders Due to Tourette Syndrome
  • Multiple Sclerosis
  • Nausea and Vomiting Related to Cancer Chemotherapy
  • Posttraumatic Stress Disorder (PTSD)
  • Sleep Problems

Depending on the use case, these medicinal products can differ in the THC/CBD profile and formulation. The effectiveness of these products depends on our understanding of how they are absorbed and used by the body. 

Agentix Biosciences has identified a targeted collection of Consumer Wellness and Pharmaceutical product opportunities, the majority of which will be designed to offer a more sophisticated and intelligent product offering in the multi-billion-dollar global Cannabinoid market. The first category consists of a series of health and wellness products that incorporate proprietary and proven cellular delivery technology for the Consumer market. Further advancements of these novel bio complexes are used in the development and production of pharma-grade products for more specific clinical (non-prescription) applications, e.g. Arthritic Joint Pain and Onychomycosis.